Finding qualified CRO/CDMO partners
Keeping projects on track
Maintaining scientific consistency
Ensuring successful knowledge transfer
Navigating global compliance
Preparing for successful launch
We help emerging biotech companies, virtual pharma companies, venture-backed start-ups, global companies entering India
We help emerging biotech companies, virtual pharma companies, venture-backed start-ups, global companies entering India
Every capability we deliver is designed to eliminate the critical risks that cause drug development programmes to fail.
Delays, poor execution, unreliable data and costly programme setbacks.
20+ years of CRO/CDMO selection experience. We identify the right teams, capabilities and partners for programme success.
Multiple vendors, unclear ownership, slow decisions and missed milestones.
Independent oversight, milestone tracking, stakeholder alignment and proactive risk management.
Knowledge gaps, transfer delays, scale-up challenges and manufacturing disruption.
Structured transfer planning, manufacturing readiness and cross-site execution support.
Compliance gaps, inspection findings, rework and submission delays.
Regulatory strategy, inspection readiness, submission support and quality compliance.
Emerging issues discovered too late, impacting timelines and budgets.
Ongoing monitoring of programme risks, partner performance and industry developments.
Independent audit and turnaround of troubled CRO/CDMO relationships or stalled development programs. We provide rapid diagnosis, corrective action plans (CAPA), and project re-baselining to save critical timelines.
Strategic oversight from lead optimization through IND filing. We provide single-point accountability for multi-partner programs, delivering a regulatory-ready data package on aggressive, predictable timelines.
Ensuring absolute IP security during cross-border transfers. We act as your technical firewall, documenting "know-how" and verifying that proprietary processes remain your exclusive asset.
Developing "Plan B" resilience. We pre-qualify secondary sources for critical intermediates or APIs, ensuring zero disruption to your commercial or clinical supply chain.
.svg)
Over two decades in the CRO/CDMO arena, I shaped and executed programs spanning discovery, preclinical, CMC development, GMP manufacturing, and early-phase clinical research across US, European, and Asia-Pacific biotech and pharma companies. I encompassed building business development teams, managing integrated drug development value chains, and bridging operational and regulatory divides between Western sponsors and Indian service providers. During this tenure, I witnessed too many programs derailed by misalignment, weak partner governance or documentation gaps; therefore, I founded Aventiq Bio with one clear mission: to deliver outsourcing to India with 100% conviction, zero surprises, and uncompromised regulatory/quality standards. I now lead Aventiq Bio in raising the benchmark — by choosing the right partner, managing the program end-to-end, and ensuring your IND/CMC success from day one. I guarantee that when you engage Aventiq Bio, you are backed by someone who’s walked both sides of the table — as a sponsor and a service provider — and demands the same discipline you expect in the US/Europe.
Press Enter to search
